Kaixiang Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kaixiang Feng has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Binghe Xu
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
1 shared publication - De-Tao Yin
Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
1 shared publication Gongbo Du
Department of Thyroid Surgery The First Affiliated Hospital of Zhengzhou University Zhengzhou China
1 shared publicationHanhui Liu
Department of Pathology and Pathophysiology Hubei Provincial Key Laboratory of Developmentally Originated Disease, TaiKang Medical School (School of Basic Medical Sciences), Wuhan University Wuhan Hubei China
1 shared publicationHongqiang Li
Department of Thyroid Surgery The First Affiliated Hospital of Zhengzhou University Zhengzhou China
1 shared publicationHui Li
Department of Pathology and Pathophysiology Hubei Provincial Key Laboratory of Developmentally Originated Disease, TaiKang Medical School (School of Basic Medical Sciences), Wuhan University Wuhan Hubei China
1 shared publication
Latest Publications
- Open Access
- 15 March 2025
- Published by Wiley in Cancer Innovation
- Vol. 4 (2) , e161
Investigating the Mechanism of IFN‐γ‐Inducible Lysosomal Thiol Reductase‐Mediated Inhibition of Breast Cancer Cell Proliferation
Background: Breast cancer has become a severe threat to human health, making it imperative to identify effective drugs and therapeutic targets.Methods: Various molecular biology experiments, such as western blot analysis, cytologic effect, co‐immunoprecipitation, and immunofluorescence assays, as well as a nude mouse xenograft tumor model, were used to comprehensively analyze the impact of gamma‐interferon‐inducible lysosomal thiol reductase (GILT) on the malignant phenotype of breast cancer cells. This work was performed to examine GILT expression levels and explore the potential mechanism in breast cancer.Results: GILT protein expression levels were significantly lower in breast cancer cells than in normal breast epithelial cells. Overexpressing GILT inhibited breast cancer cell proliferation and migration and slowed tumor growth. GILT inhibited the interaction between the MYC and WDR5 transcription complex and played a tumor‐suppressive role. The MYC/WDR5 transcription complex inhibitor OICR‐9429 could synergize with GILT to inhibit breast cancer cell proliferation.Conclusion: This study reveals a potential mechanism by which GILT can slow breast cancer growth, as well as identifying the possible clinical application value of small molecule inhibitor OICR‐9429. These data collectively provide novel treatment strategies for breast cancer therapy.
- 15 March 2025
- Published by Wiley in Cancer Innovation
- Vol. 4 (2) , e161
Open AccessInvestigating the Mechanism of IFN‐γ‐Inducible Lysosomal Thiol Reductase‐Mediated Inhibition of Breast Cancer Cell Proliferation
Background: Breast cancer has become a severe threat to human health, making it imperative to identify effective drugs and therapeutic targets.Methods: Various molecular biology experiments, such as western blot analysis, cytologic effect, co‐immunoprecipitation, and immunofluorescence assays, as well as a nude mouse xenograft tumor model, were used to comprehensively analyze the impact of gamma‐interferon‐inducible lysosomal thiol reductase (GILT) on the malignant phenotype of breast cancer cells. This work was performed to examine GILT expression levels and explore the potential mechanism in breast cancer.Results: GILT protein expression levels were significantly lower in breast cancer cells than in normal breast epithelial cells. Overexpressing GILT inhibited breast cancer cell proliferation and migration and slowed tumor growth. GILT inhibited the interaction between the MYC and WDR5 transcription complex and played a tumor‐suppressive role. The MYC/WDR5 transcription complex inhibitor OICR‐9429 could synergize with GILT to inhibit breast cancer cell proliferation.Conclusion: This study reveals a potential mechanism by which GILT can slow breast cancer growth, as well as identifying the possible clinical application value of small molecule inhibitor OICR‐9429. These data collectively provide novel treatment strategies for breast cancer therapy.
- Open Access
- 20 February 2025
- Published by Wiley in Cancer Innovation
- Vol. 4 (2) , e159
Artificial Intelligence and Breast Cancer Management: From Data to the Clinic
Breast cancer (BC) remains a significant threat to women's health worldwide. The oncology field had an exponential growth in the abundance of medical images, clinical information, and genomic data. With its continuous advancement and refinement, artificial intelligence (AI) has demonstrated exceptional capabilities in processing intricate multidimensional BC‐related data. AI has proven advantageous in various facets of BC management, encompassing efficient screening and diagnosis, precise prognosis assessment, and personalized treatment planning. However, the implementation of AI into precision medicine and clinical practice presents ongoing challenges that necessitate enhanced regulation, transparency, fairness, and integration of multiple clinical pathways. In this review, we provide a comprehensive overview of the current research related to AI in BC, highlighting its extensive applications throughout the whole BC cycle management and its potential for innovative impact. Furthermore, this article emphasizes the significance of constructing patient‐oriented AI algorithms. Additionally, we explore the opportunities and potential research directions within this burgeoning field.
- 20 February 2025
- Published by Wiley in Cancer Innovation
- Vol. 4 (2) , e159
Open AccessArtificial Intelligence and Breast Cancer Management: From Data to the Clinic
Breast cancer (BC) remains a significant threat to women's health worldwide. The oncology field had an exponential growth in the abundance of medical images, clinical information, and genomic data. With its continuous advancement and refinement, artificial intelligence (AI) has demonstrated exceptional capabilities in processing intricate multidimensional BC‐related data. AI has proven advantageous in various facets of BC management, encompassing efficient screening and diagnosis, precise prognosis assessment, and personalized treatment planning. However, the implementation of AI into precision medicine and clinical practice presents ongoing challenges that necessitate enhanced regulation, transparency, fairness, and integration of multiple clinical pathways. In this review, we provide a comprehensive overview of the current research related to AI in BC, highlighting its extensive applications throughout the whole BC cycle management and its potential for innovative impact. Furthermore, this article emphasizes the significance of constructing patient‐oriented AI algorithms. Additionally, we explore the opportunities and potential research directions within this burgeoning field.
- Open Access
- 2 December 2021
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 36 (1) , e24148
Upregulated SLC27A2/FATP2 in differentiated thyroid carcinoma promotes tumor proliferation and migration
Background: Differentiated thyroid carcinoma (DTC) accounts for the vast majority of thyroid cancer (TC) cases. The rapidly increasing incidence of TC requires the urgent identification of new diagnostic and therapeutic targets. Solute carrier family 27 member 2 (SLC27A2/FATP2) plays an essential role in lipid biosynthesis and fatty acid transport. Recent studies have confirmed its involvement in a variety of diseases, including cancer.Methods: In this study, the expression of SLC27A2 was analyzed in cancer and paracancerous tissue samples from 98 thyroid cancer patients, and we performed ROC analysis to confirm the diagnostic value. CCK8, Transwell, and other methods were used to study its effect on DTC, and the mechanism of SLC27A2 was investigated by RNA sequencing and Western blot.Results: The expression of SLC27A2 was upregulated in both DTC tissues and cell lines and was correlated with clinical progression. In vitro studies further confirmed that SLC27A2 knockdown attenuated the proliferation and invasion of DTC cells. Through RNA sequence analysis and gene set enrichment analysis, we found that the MAPK pathway is the main downstream signaling pathway for the regulation by SLC27A2. SLC27A2 affects cell proliferation and differentiation by inducing changes in the proto‐oncogene C‐FOS.Conclusions: Our results show that SLC27A2 plays an important role in tumor proliferation and migration, providing a new putative target for the diagnosis and treatment of TC.
- 2 December 2021
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 36 (1) , e24148
Open AccessUpregulated SLC27A2/FATP2 in differentiated thyroid carcinoma promotes tumor proliferation and migration
Background: Differentiated thyroid carcinoma (DTC) accounts for the vast majority of thyroid cancer (TC) cases. The rapidly increasing incidence of TC requires the urgent identification of new diagnostic and therapeutic targets. Solute carrier family 27 member 2 (SLC27A2/FATP2) plays an essential role in lipid biosynthesis and fatty acid transport. Recent studies have confirmed its involvement in a variety of diseases, including cancer.Methods: In this study, the expression of SLC27A2 was analyzed in cancer and paracancerous tissue samples from 98 thyroid cancer patients, and we performed ROC analysis to confirm the diagnostic value. CCK8, Transwell, and other methods were used to study its effect on DTC, and the mechanism of SLC27A2 was investigated by RNA sequencing and Western blot.Results: The expression of SLC27A2 was upregulated in both DTC tissues and cell lines and was correlated with clinical progression. In vitro studies further confirmed that SLC27A2 knockdown attenuated the proliferation and invasion of DTC cells. Through RNA sequence analysis and gene set enrichment analysis, we found that the MAPK pathway is the main downstream signaling pathway for the regulation by SLC27A2. SLC27A2 affects cell proliferation and differentiation by inducing changes in the proto‐oncogene C‐FOS.Conclusions: Our results show that SLC27A2 plays an important role in tumor proliferation and migration, providing a new putative target for the diagnosis and treatment of TC.